Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study Meeting Abstract
| Authors: | Trudel, S.; Cohen, A. D.; Krishnan, A. Y.; Fonseca, R.; Spencer, A.; Berdeja, J. G.; Lesokhin, A.; Forsberg, P. A.; Laubach, J. P.; Costa, L. J.; Rodriguez-Otero, P.; Kaedbey, R.; Richter, J.; Mateos, M. V.; Thomas, S. K.; Wong, C.; Li, M. S.; Choeurng, V.; Vaze, A.; Samineni, D.; Sumiyoshi, T.; Cooper, J.; Harrison, S. J. |
| Abstract Title: | Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398800155 |
| DOI: | 10.1182/blood-2021-147983 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 157 -- Hybrid meeting, also took place online -- Source: Wos |
